| Serial Number | 87763015 |
| Word Mark | NAVIOGPS |
| Filing Date | Friday, January 19, 2018 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, September 13, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 13, 2020 |
| Goods and Services | Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagents and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products; providing personalized molecular tumor for each patient, namely, providing medical research information regarding personalized molecular tumor treatments; providing medical research and scientific research information in the field of oncology via the Internet; development of a personalized ctDNA (circulating tumor DNA) assay; molecular profiling for scientific research; providing RNA expression analysis for scientific research purposes |
| Goods and Services | Medical services in the field of oncology, nephrology; dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; physician support services in the nature of providing medical consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare medical counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship information, namely, providing comprehensive medical treatment programs involving drug therapy, and other related medical information in the field of oncology; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer; providing RNA expression analysis for medical treatment and diagnosis; providing personalized immunotherapy; providing standard diagnostics and comprehensive diagnostics, namely, providing standard and comprehensive medical testing for diagnostic purposes; medical services, namely, providing personalized drug screening; providing realtime therapeutic response monitoring for medical treatment and diagnostic purposes; provide individualized expert medical advice and diagnosis in the field of oncology; provide machine learning based medical treatment for cancer patients; providing personalized drug screening for medical treatment and diagnostic purposes; provide machine learning based treatment in the nature of medical treatment and diagnostic purposes for cancer patients |
| Goods and Services | Physician support services in the nature of providing legal consultation in the dispensing of prescription drugs for persons with particular cancers; providing survivorship information in the field of oncology, namely, legal advice regarding survivorship; provide individualized expert legal advice and diagnosis |
| Pseudo Mark | NAVIO GPS |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 31, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 31, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, November 9, 2018 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Navio Theragnostics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94401 |
| Party Name | Navio Theragnostics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Mateo, CA 94401 |
| Event Date | Event Description |
| Monday, September 13, 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, September 13, 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, February 9, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, December 23, 2020 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Friday, November 13, 2020 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, October 13, 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 13, 2020 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 23, 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, September 9, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, August 31, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Monday, August 31, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, August 31, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Monday, August 31, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, August 31, 2020 | EXAMINER'S AMENDMENT ENTERED |
| Monday, August 31, 2020 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, August 31, 2020 | EXAMINERS AMENDMENT E-MAILED |
| Monday, August 31, 2020 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, February 18, 2020 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, February 18, 2020 | FINAL REFUSAL E-MAILED |
| Tuesday, February 18, 2020 | FINAL REFUSAL WRITTEN |
| Friday, January 24, 2020 | LIE CHECKED SUSP - TO ATTY FOR ACTION |
| Wednesday, June 19, 2019 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Friday, June 14, 2019 | ASSIGNED TO LIE |
| Thursday, November 29, 2018 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, November 29, 2018 | LETTER OF SUSPENSION E-MAILED |
| Thursday, November 29, 2018 | SUSPENSION LETTER WRITTEN |
| Friday, November 9, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, November 8, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, November 8, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, May 8, 2018 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, May 8, 2018 | NON-FINAL ACTION E-MAILED |
| Tuesday, May 8, 2018 | NON-FINAL ACTION WRITTEN |
| Monday, April 30, 2018 | ASSIGNED TO EXAMINER |
| Wednesday, January 31, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, January 23, 2018 | NEW APPLICATION ENTERED IN TRAM |